BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25296077)

  • 61. Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer.
    Wist EA; Sommer HH; Ostenstad B; Risberg T; Bremnes Y; Mjaaland I
    Acta Oncol; 2004; 43(2):186-9. PubMed ID: 15163168
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Adherence with oral oncologic treatment in cancer patients: interest of an adherence score of all dosing errors.
    Thivat E; Van Praagh I; Belliere A; Mouret-Reynier MA; Kwiatkowski F; Durando X; Mahammedi H; Dillies AF; Chollet P; Chevrier R
    Oncology; 2013; 84(2):67-74. PubMed ID: 23128040
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of protracted infusion 5-fluorouracil and capecitabine in adjuvant chemoradiotherapy for rectal cancer.
    Kurt M; Ozkan L; Kurt E; Cetintas SK; Aygun S; Ercan I; Yilmazlar T; Memik F
    Hepatogastroenterology; 2008; 55(85):1158-63. PubMed ID: 18795649
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Two-week course of preoperative chemoradiotherapy followed by delayed surgery for rectal cancer: a phase II multi-institutional clinical trial (KROG 11-02).
    Lee JH; Kim JG; Oh ST; Lee MA; Chun HG; Kim DY; Kim TH; Kim SY; Baek JY; Park JW; Oh JH; Park HC; Choi DH; Park YS; Kim HC; Chie EK; Jang HS
    Radiother Oncol; 2014 Jan; 110(1):150-4. PubMed ID: 24411228
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Oral combination chemotherapy with capecitabine and cyclophosphamide in combination with endocrine therapy and anti-HER2 therapy for advanced and metastatic breast cancer].
    Okamura R; Kato T; Sata R
    Nihon Rinsho; 2012 Sep; 70 Suppl 7():592-6. PubMed ID: 23350469
    [No Abstract]   [Full Text] [Related]  

  • 66. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Dunst J; Reese T; Sutter T; Zühlke H; Hinke A; Kölling-Schlebusch K; Frings S
    J Clin Oncol; 2002 Oct; 20(19):3983-91. PubMed ID: 12351595
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
    Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A
    J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial.
    Glen H; Cassidy J
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):547-51. PubMed ID: 18402521
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Adherence to capecitabine treatment and contributing factors among cancer patients in Malaysia.
    Zahrina AK; Norsa'adah B; Hassan NB; Norazwany Y; Norhayati I; Roslan MH; Wan Nazuha WR
    Asian Pac J Cancer Prev; 2014; 15(21):9225-32. PubMed ID: 25422205
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Efficacy of docetaxel combined capecitabine on metastatic breast cancer].
    Wang XX; Zhou ZM; Yuan ZY; Zhang DS; Shi YX; Jiang WQ
    Ai Zheng; 2007 Apr; 26(4):407-10. PubMed ID: 17430662
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer--how low can you go?
    Yap YS; Kendall A; Walsh G; Banerji U; Johnston SR; Smith IE; O'Brien M
    Breast; 2007 Aug; 16(4):420-4. PubMed ID: 17379519
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
    Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
    J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Adherence to capecitabine in preoperative treatment of stage II and III rectal cancer: do we need to worry?
    Font R; Espinas JA; Layos L; Martinez Villacampa M; Capdevila J; Tobeña M; Pisa A; Pericay C; Lezcano C; Fort E; Cardona I; Berga N; Solà J; Borras JM
    Ann Oncol; 2017 Apr; 28(4):831-835. PubMed ID: 28327898
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Oral cancer chemotherapy adherence and adherence assessment tools: a report from North Central Cancer Group Trial N0747 and a systematic review of the literature.
    Patel K; Foster NR; Farrell A; Le-Lindqwister NA; Mathew J; Costello B; Reynolds J; Meyers JP; Jatoi A
    J Cancer Educ; 2013 Dec; 28(4):770-6. PubMed ID: 23872949
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Mobile health for drug dose optimisation.
    Larsen ME; Farmer A; Weaver A; Young A; Tarassenko L
    Annu Int Conf IEEE Eng Med Biol Soc; 2011; 2011():1540-3. PubMed ID: 22254614
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Compliance with adjuvant capecitabine in patients with stage II and III colon cancer: comparison of administrative versus medical record data.
    Amlani A; Kumar A; Ruan JY; Cheung WY
    Cancer Med; 2016 Aug; 5(8):1776-82. PubMed ID: 27228415
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Paraneoplastic stiff person syndrome associated with colon cancer misdiagnosed as idiopathic Parkinson's disease worsened after capecitabine therapy.
    Badzek S; Miletic V; Prejac J; Gorsic I; Golem H; Bilic E; Kekez D; Librenjak N; Plestina S
    World J Surg Oncol; 2013 Sep; 11():224. PubMed ID: 24028681
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Evaluation of the practice of prescribing oral chemotherapy type "Capecitabine" by medical oncologist: A first study from Morocco].
    Kharmoum S; Najdi A; Rahhali R; Meliani M; Boutayeb S; Mrabti H; El Ghissassi I; Afqir S; Mellas N; Ichou M; El M'Rabet FZ; Errihani H
    Bull Cancer; 2021 Oct; 108(10):940-947. PubMed ID: 34281729
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The Effect of Telephone-Based Follow-Up on Adherence, Efficacy, and Toxicity of Oral Capecitabine-Based Chemotherapy.
    Eldeib HK; Abbassi MM; Hussein MM; Salem SE; Sabry NA
    Telemed J E Health; 2019 Jun; 25(6):462-470. PubMed ID: 30048216
    [No Abstract]   [Full Text] [Related]  

  • 80. Adherence to oral chemotherapy among colorectal cancer patients: A longitudinal study.
    Chen Y; Wu X; Xian X; Zhang Y; Gong N; Qin H; Zhang M
    Eur J Oncol Nurs; 2020 Oct; 48():101822. PubMed ID: 32947157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.